Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 638-646

  Corona, Giuseppe ^a   Elia, Caterina ^a   Casetta, Bruno ^b   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b MDS SCIEX   (Canada)

Author keywords

clinical pharmacology; irinotecan; LC MS MS; metabolism; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLON CANCER; DRUG METABOLISM; DRUG MONITORING; FAST LIQUID CHROMATROGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; GLUCURONIDES; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 77957258993     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ec3bf5     Document Type: Article

References (19)

1. Sawada S, Okajima S, Aiyama R, et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull (Tokyo). 1991;39:1446-1450.
2. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32:491-503.
3. Vredenburgh JJ, Desjardins A, Reardon DA, et al. Experience with irinotecan for the treatment of malignant glioma. Neurol Oncol 2009; 11:80-91.
4. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7: 2182-2194.
5. de Jong FA, Mathijssen RH, Xie R, et al. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res. 2004;10:4068-4071.
6. Di Paolo A, Bocci G, Danesi R, et al. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol. 2006;1:311-323.
7. Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDPglucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit. 2002;24:111-116.
8. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27:2604-2614.
9. Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther. 2008;83:601-606.
10. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol. 2007;25:2719-2726.
11. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24:104-123.
12. Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem. 2007;388:1327-1349.
13. D'Esposito F, Tattam BN, Ramzan I, et al. A liquid chromatography/ electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;875:522-530.
14. Khan S, Ahmad A, Ahmad I. A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7- ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN-38). Biomed Chromatogr. 2003;17: 493-499.
15. Zhang W, Dutschman GE, Li X, et al. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3038-3044.
16. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for the Industry: bioanalytical method validation. US Food and Drug Administration [ 2001]. 2007. Available at: www.fda.gov/ CDER/GUIDANCE/4252fnl. htm. Accessed June 1, 2010.
17. Van Eeckhaut A, Lanckmans K, Sarre S, et al. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2198-2207.
18. Poujol S, Pinguet F, Malosse F, et al. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin Chem. 2003;49: 1900-1908.
19. Rivory LP, Chatelut E, Canal P, et al. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 1994; 54:6330-6333.